Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

IL-6 production inhibitors in early development at Ono

Nov. 15, 2002

Seattle Genetics releases clinical and preclinical updates

Nov. 14, 2002

Oregovomab enhances killer T-cell responses in apoptotic ovarian cancer cells

Nov. 14, 2002

Preclinical antitumor activity of the anti-CD80 antibody IDEC-114

Nov. 13, 2002

HuMax-CD4 to be tested in cancer patients

Nov. 12, 2002

First patient enrolled in prostate cancer trial with Norelin

Nov. 11, 2002

Uvidem enters phase II for metastatic melanoma

Nov. 7, 2002

MDX-010 program expands with phase II trials in metastatic melanoma and prostate cancer

Nov. 6, 2002

Promising early clinical results for dexosome vaccine in melanoma

Nov. 5, 2002

G17DT increases median survival time of patients with advanced pancreatic cancer

Oct. 31, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 12, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
LINC01116 has prognostic value in lung cancer, study shows
BioWorld Science
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...